- Home
- GSRT vs NGNE Comparison
GSRT vs NGNE Comparison
Compare GSRT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSRT
- NGNE
- Stock Information
- Founded
- GSRT 2023
- NGNE 2003
- Country
- GSRT United States
- NGNE United States
- Employees
- GSRT N/A
- NGNE N/A
- Industry
- GSRT
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- GSRT
- NGNE Health Care
- Exchange
- GSRT Nasdaq
- NGNE Nasdaq
- Market Cap
- GSRT 302.2M
- NGNE 325.3M
- IPO Year
- GSRT 2024
- NGNE N/A
- Fundamental
- Price
- GSRT $10.37
- NGNE $18.48
- Analyst Decision
- GSRT Strong Buy
- NGNE Strong Buy
- Analyst Count
- GSRT 1
- NGNE 7
- Target Price
- GSRT $19.00
- NGNE $41.86
- AVG Volume (30 Days)
- GSRT 518.2K
- NGNE 110.1K
- Earning Date
- GSRT 01-01-0001
- NGNE 08-11-2025
- Dividend Yield
- GSRT N/A
- NGNE N/A
- EPS Growth
- GSRT N/A
- NGNE N/A
- EPS
- GSRT 0.19
- NGNE N/A
- Revenue
- GSRT N/A
- NGNE N/A
- Revenue This Year
- GSRT N/A
- NGNE N/A
- Revenue Next Year
- GSRT N/A
- NGNE N/A
- P/E Ratio
- GSRT $53.45
- NGNE N/A
- Revenue Growth
- GSRT N/A
- NGNE N/A
- 52 Week Low
- GSRT $9.86
- NGNE $6.88
- 52 Week High
- GSRT $11.49
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- GSRT 40.74
- NGNE 35.93
- Support Level
- GSRT $10.36
- NGNE $19.59
- Resistance Level
- GSRT $10.40
- NGNE $20.46
- Average True Range (ATR)
- GSRT 0.08
- NGNE 1.23
- MACD
- GSRT 0.01
- NGNE -0.20
- Stochastic Oscillator
- GSRT 14.67
- NGNE 13.37
About GSRT GSR III Acquisition Corp. Ordinary Shares
GSR III Acquisition Corp is a blank check company.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.